What You Should Know:

您应该知道：

– Deliberate AI, a digital health company harnessing AI to revolutionize mental health assessment, has secured a major milestone in its mission. The U.S. Food and Drug Administration (FDA) has selected Deliberate AI’s AI-generated Clinical Outcome Assessment (AI-COA™) for its Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program..

–刻意人工智能是一家利用人工智能彻底改变心理健康评估的数字健康公司，在其使命中取得了重大里程碑。美国食品和药物管理局（FDA）选择了人工智能人工智能产生的临床结果评估（AI-COA）™) 创新的新药科技方法（ISTAND）试点项目。。

– The collaboration between Deliberate AI and the FDA represents a giant leap in the fight against mental illness. By harnessing the power of AI, we can accelerate drug development, improve treatment efficacy, and ultimately empower patients to live healthier, happier lives

–故意人工智能与FDA之间的合作代表了对抗精神疾病的巨大飞跃。通过利用人工智能的力量，我们可以加速药物开发，提高治疗效果，并最终赋予患者更健康，更幸福的生活

AI-COA™: A Beacon of Precision in Mental Health

AI-COA公司™: 心理健康精准的灯塔

Deliberate AI’s AI-COA™ leverages cutting-edge multimodal signal processing and machine learning to capture mental health symptoms quantitatively. This novel approach offers several advantages over traditional methods:

深思熟虑的AI的AI-COA™ 利用尖端的多模式信号处理和机器学习来定量捕捉心理健康症状。与传统方法相比，这种新颖的方法具有几个优点：

Objectivity and consistency: AI-COA™ removes human bias and subjectivity, providing a consistent and reliable assessment method.Enhanced precision: The AI algorithm analyzes subtle behavioral cues, offering a more granular picture of symptom severity than traditional questionnaires.Real-time insights: AI-COA™ can continuously monitor patients throughout clinical trials, providing valuable data for researchers..

客观性和一致性：AI-COA™ 消除人为偏见和主观性，提供一致可靠的评估方法。提高精确度：人工智能算法分析微妙的行为线索，提供比传统问卷更精细的症状严重程度图片。实时见解：AI-COA™ 可以在整个临床试验过程中持续监测患者，为研究人员提供有价值的数据。。

FDA Recognition: A Turning Point for Mental Health Research

FDA认可：心理健康研究的转折点

The FDA’s inclusion of AI-COA™ in the ISTAND program signifies a critical turning point in mental health research. This is the first time the agency has embraced an AI/ML and Digital Health Technology (DHT) initiative for the program, and it also marks the inaugural project in Psychiatry and Neuroscience to join the pilot.

FDA将AI-COA纳入™ ISTAND计划的实施标志着心理健康研究的一个关键转折点。这是该机构首次为该计划接受AI/ML和数字健康技术（DHT）倡议，这也标志着精神病学和神经科学领域的首次项目加入试点。

This recognition underscores the FDA’s commitment to fostering innovation in drug development and evaluation, particularly in the field of mental health where traditional methods have limitations..

这一认可强调了FDA致力于促进药物开发和评估的创新，特别是在传统方法有局限性的心理健康领域。。

“The FDA’s recognition – including Deliberate’s AI-COA™in this program – heralds a new epoch in developing and monitoring treatments for Depression and Anxiety,” said Marc Aafjes, Founder & CEO of Deliberate AI. “Together, we can pave the way for more powerful, efficient, and faster clinical trials, addressing a critical barrier in psychiatric drug development, ultimately leading to enhanced patient care and a profound public health impact.”.

“FDA的认可-包括故意的AI-COA™故意人工智能创始人兼首席执行官马克·阿夫杰斯（MarcAafjes）说：“在这个项目中，预示着开发和监测抑郁症和焦虑症治疗方法的新纪元。我们可以共同为更强大、高效和更快的临床试验铺平道路，解决精神病药物开发中的关键障碍，最终提高患者护理水平，并对公共卫生产生深远影响。”。